Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2024-05-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国浩律师（杭州）事务所关于国邦医药2023年年度股东大会法律意见书
Regulatory Filings
2024-05-08 Chinese
国邦医药关于股东减持股份进展暨权益变动超过1%的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement about the progress of a shareholder's reduction in shareholding and changes in equity exceeding 1%. It includes specifics about the shareholders involved, the number of shares reduced, the percentage of total shares, the methods of reduction, and risk disclosures. The document is not a financial report, earnings release, or management discussion. It is a regulatory disclosure about shareholding changes by significant shareholders. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length is 3820 characters, which is sufficient for a detailed notification rather than a brief announcement or a report publication announcement. Therefore, the correct classification is MRQ with high confidence.
2024-05-08 Chinese
国邦医药关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company Guobang Pharmaceutical Group Co., Ltd. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but reports on the status of the company's buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-04-30 Chinese
国邦医药关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding changes in shareholder equity stakes, specifically detailing the reduction in shareholding percentages by certain investors. It includes information about the shareholders, the number of shares held before and after the change, and confirms that the change does not affect control of the company. The document references relevant securities laws and disclosure requirements but does not contain financial statements or detailed financial analysis. It is a notification of a change in major shareholding levels, fitting the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2024-04-26 Chinese
简式权益变动报告书（浙民投恒华、丝路基金）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding by specific entities in 国邦医药集团股份有限公司, including the number of shares held before and after the transaction, the method of transaction (block trade), and the percentage of total shares. It also includes declarations and legal compliance statements related to the equity change. There is no indication of financial performance data, earnings, management changes, or other report types. The document is a formal notification of changes in significant share ownership levels, consistent with the definition of Major Shareholding Notification (MRQ). The document length (8404 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is MRQ with high confidence.
2024-04-26 Chinese
国邦医药关于持股5%以上股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement by Guobang Pharmaceutical Group Co., Ltd. regarding a planned reduction in shareholding by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number and percentage of shares to be reduced, the methods and timing of the reduction, and related risk disclosures. The content focuses on shareholding changes and reduction plans by significant shareholders, which aligns with notifications about major shareholding changes. The document is not a financial report, earnings release, or management discussion, nor is it a regulatory certification or a report publication announcement. It fits the category of Major Shareholding Notification, which covers notifications of changes in significant share ownership levels crossing thresholds.
2024-04-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.